nach oben

Cancer and Metastasis Reviews

Erschienen in:

20.03.2017

Metastatic melanoma moves on: translational science in the era of personalized medicine

verfasst von: Mitchell P. Levesque, Phil F. Cheng, Marieke I.G. Raaijmakers, Annalisa Saltari, Reinhard Dummer

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Progress in understanding and treating metastatic melanoma is the result of decades of basic and translational research as well as the development of better in vitro tools for modeling the disease. Here, we review the latest therapeutic options for metastatic melanoma and the known genetic and non-genetic mechanisms of resistance to these therapies, as well as the in vitro toolbox that has provided the greatest insights into melanoma progression. These include next-generation sequencing technologies and more complex 2D and 3D cell culture models to functionally test the data generated by genomics approaches. The combination of hypothesis generating and hypothesis testing paradigms reviewed here will be the foundation for the next phase of metastatic melanoma therapies in the coming years.

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996). Enhancement of antitumor immunity by CTLA-4 blockade. Science, 271(5256), 1734–1736.PubMedCrossRef

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., et al. (2002). Mutations of the BRAF gene in human cancer. Nature, 417(6892), 949–954. doi:10.1038/nature00766.PubMedCrossRef

Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., et al. (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proceedings of the National Academy of Sciences of the United States of America, 105(8), 3041–3046.PubMedPubMedCentralCrossRef

Raaijmakers, M. I., Rozati, S., Goldinger, S. M., Widmer, D. S., Dummer, R., & Levesque, M. P. (2013). Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy, 5(2), 169–182. doi:10.2217/imt.12.162.PubMedCrossRef

Widmer, D. S., Eichhoff, O. M., Dummer, R., & Levesque, M. P. (2015). Melanoma’s next top model, it is in the air. Experimental Dermatology, 24(9), 659–660. doi:10.1111/exd.12757.

Dummer, R., Siano, M., Hunger, R. E., Lindenblatt, N., Braun, R., Michielin, O., et al. (2016). The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Medical Weekly, 146, w14279. doi:10.4414/smw.2016.14279.PubMed

Flaherty, K. T., Lee, S. J., Zhao, F., Schuchter, L. M., Flaherty, L., Kefford, R., et al. (2013). Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. [clinical trial, phase III randomized controlled trial]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31(3), 373–379. doi:10.1200/JCO.2012.42.1529.CrossRef

Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., et al. (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. [clinical trial, phase III randomized controlled trial research support, non-U.S. Gov’t]. Journal of Clinical Oncology, 27(17), 2823–2830. doi:10.1200/JCO.2007.15.7636.PubMedCrossRef

Falchook, G. S., Long, G. V., Kurzrock, R., Kim, K. B., Arkenau, T. H., Brown, M. P., et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. [clinical trial, phase I multicenter study research support, non-U.S. Gov’t]. Lancet, 379(9829), 1893–1901. doi:10.1016/S0140-6736(12)60398-5.PubMedPubMedCentralCrossRef

10.

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. [clinical trial, phase I multicenter study research support, non-U.S. Gov’t]. The New England Journal of Medicine, 363(9), 809–819. doi:10.1056/NEJMoa1002011.PubMedPubMedCentralCrossRef

11.

Sharfman, W. H., Hodi, F. S., Lawrence, D. P., Flaherty, K. T., Amaravadi, R. K., Kim, K. B., et al. 2011. Results from the first-in-human (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma. In ASCO, Chicago, IL (Vol. 29: (suppl; abstr 8508)). J Clin Oncol.

12.

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. [clinical trial, phase III comparative study multicenter study randomized controlled trial research support, non-U.S. Gov’t]. The New England Journal of Medicine, 364(26), 2507–2516. doi:10.1056/NEJMoa1103782.PubMedPubMedCentralCrossRef

13.

Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., et al. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. The New England Journal of Medicine. doi:10.1056/NEJMoa1203421.

14.

Hauschild, A., Grob, J. J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet, 380(9839), 358–365. doi:10.1016/S0140-6736(12)60868-X.PubMedCrossRef

15.

Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England Journal of Medicine. doi:10.1056/NEJMoa1210093.

16.

Kefford, R., Miller, W. H., Jr., Tan, D. S.-W., Sullivan, R. J., Long, G. V., Tai, W. M. D., et al. 2013. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. In ASCO, Chicago (Vol. 9029).

17.

Larkin, J., Ascierto, P. A., Dreno, B., Atkinson, V., Liszkay, G., Maio, M., et al. (2014). Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. The New England Journal of Medicine, 371(20), 1867–1876. doi:10.1056/NEJMoa1408868.PubMedCrossRef

18.

Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., et al. (2014). Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. The New England Journal of Medicine, 371(20), 1877–1888. doi:10.1056/NEJMoa1406037.PubMedCrossRef

19.

Ribas, A., Gonzalez, R., Pavlick, A., Hamid, O., Gajewski, T. F., Daud, A., et al. (2014). Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. The Lancet Oncology, 15(9), 954–965. doi:10.1016/S1470-2045(14)70301-8.PubMedCrossRef

20.

Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroyakovsky, D., et al. 2014. COMBI-v: A randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (V) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. In European Society for Medical Oncology, Madrid, Spain (pp. ID 5768; LBA5764_PR).

21.

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England Journal of Medicine, 364(26), 2507–2516. doi:10.1056/NEJMoa1103782.PubMedPubMedCentralCrossRef

22.

Navin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., et al. (2011). Tumour evolution inferred by single-cell sequencing. Nature, 472(7341), 90–94.PubMedPubMedCentralCrossRef

23.

Jeffrey Alan Sosman, Anna C. Pavlick, Lynn Mara Schuchter, Karl D Lewis, Grant A. McArthur, Charles Lance Cowey, Stergios J Moschos, Keith T. Flaherty, Kevin B. Kim, Jeffrey Weber, Peter Hersey, Georgina V. Long, Donald P. Lawrence, Mark Kockx, Olivia Spleiss, Astrid Koehler, Gideon Bollag, Andrew K. Joe, Kerstin Trunzer, Antoni Ribas (2012). Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma. 2012 ASCO Annual Meeting (abstr 8503).

24.

Trunzer, K., Pavlick, A. C., Schuchter, L., Gonzalez, R., McArthur, G. A., Hutson, T. E., et al. (2013). Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Journal of Clinical Oncology, 31(14), 1767–1774. doi:10.1200/JCO.2012.44.7888.PubMedCrossRef

25.

Emery, C. M., Vijayendran, K. G., Zipser, M. C., Sawyer, A. M., Niu, L., Kim, J. J., et al. (2009). MEK1 mutations confer resistance to MEK and B-RAF inhibition. [comparative study research support, N.I.H., extramural research support, non-U.S. Gov’t]. Proceedings of the National Academy of Sciences of the United States of America, 106(48), 20411–20416. doi:10.1073/pnas.0905833106.PubMedPubMedCentralCrossRef

26.

Van Allen, E. M., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., et al. (2014). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discovery, 4(1), 94–109. doi:10.1158/2159-8290.CD-13-0617.PubMedCrossRef

27.

Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 468(7326), 973–977. doi:10.1038/nature09626.PubMedPubMedCentralCrossRef

28.

Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., et al. (2014). Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discovery, 4(1), 80–93. doi:10.1158/2159-8290.CD-13-0642.PubMedCrossRef

29.

Raaijmakers, M. I., Widmer, D. S., Narechania, A., Eichhoff, O., Freiberger, S. N., Wenzina, J., et al. (2016). Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget, 7(47), 77163–77174. doi:10.18632/oncotarget.12848.PubMedPubMedCentral

30.

Oberholzer, P. A., Kee, D., Dziunycz, P., Sucker, A., Kamsukom, N., Jones, R., et al. (2012). RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. Journal of Clinical Oncology, 30(3), 316–321. doi:10.1200/JCO.2011.36.7680.PubMedCrossRef

31.

Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., et al. (2012). RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. [clinical trial, phase I clinical trial, phase II clinical trial, phase III research support, non-U.S. Gov’t]. The New England Journal of Medicine, 366(3), 207–215. doi:10.1056/NEJMoa1105358.PubMedPubMedCentralCrossRef

32.

Lin, W. M., Baker, A. C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J. M., et al. (2008). Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Research, 68(3), 664–673.PubMedCrossRef

33.

Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., et al. (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 480(7377), 387–390. doi:10.1038/nature10662.PubMedPubMedCentralCrossRef

34.

Zipser, M. C., Eichhoff, O. M., Widmer, D. S., Schlegel, N. C., Schoenewolf, N. L., Stuart, D., et al. (2011). A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status. Pigment Cell & Melanoma Research, 24(2), 326–333. doi:10.1111/j.1755-148X.2010.00823.x.CrossRef

35.

Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., et al. (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell, 18(6), 683–695. doi:10.1016/j.ccr.2010.11.023.PubMedPubMedCentralCrossRef

36.

Vergani, E., Vallacchi, V., Frigerio, S., Deho, P., Mondellini, P., Perego, P., et al. (2011). Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032. [research support, non-U.S. Gov’t]. Neoplasia, 13(12), 1132–1142.PubMedPubMedCentralCrossRef

37.

Montagut, C., Sharma, S. V., Shioda, T., McDermott, U., Ulman, M., Ulkus, L. E., et al. (2008). Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. [research support, N.I.H., extramural research support, non-U.S. Gov’t]. Cancer Research, 68(12), 4853–4861. doi:10.1158/0008-5472.CAN-07-6787.PubMedPubMedCentralCrossRef

38.

Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468(7326), 968–972. doi:10.1038/nature09627.PubMedPubMedCentralCrossRef

39.

Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 487(7408), 500–504. doi:10.1038/nature11183.PubMedPubMedCentralCrossRef

40.

Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., et al. (2012). Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 487(7408), 505–509. doi:10.1038/nature11249.PubMedPubMedCentralCrossRef

41.

Girotti, M. R., Pedersen, M., Sanchez-Laorden, B., Viros, A., Turajlic, S., Niculescu-Duvaz, D., et al. (2013). Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discovery, 3(2), 158–167. doi:10.1158/2159-8290.CD-12-0386.PubMedCrossRef

42.

Sun, C., Wang, L., Huang, S., Heynen, G. J., Prahallad, A., Robert, C., et al. (2014). Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 508(7494), 118–122. doi:10.1038/nature13121.PubMedCrossRef

43.

Boussemart, L., Malka-Mahieu, H., Girault, I., Allard, D., Hemmingsson, O., Tomasic, G., et al. (2014). eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. Nature, 513(7516), 105–109. doi:10.1038/nature13572.PubMedCrossRef

44.

Menon, D. R., Das, S., Krepler, C., Vultur, A., Rinner, B., Schauer, S., et al. (2015). A stress-induced early innate response causes multidrug tolerance in melanoma. Oncogene, 34(34), 4545. doi:10.1038/onc.2014.432.PubMedCrossRef

45.

Roesch, A., Fukunaga-Kalabis, M., Schmidt, E. C., Zabierowski, S. E., Brafford, P. A., Vultur, A., et al. (2010). A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell, 141(4), 583–594. doi:10.1016/j.cell.2010.04.020.PubMedPubMedCentralCrossRef

46.

Roesch, A., Vultur, A., Bogeski, I., Wang, H., Zimmermann, K. M., Speicher, D., et al. (2013). Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell, 23(6), 811–825. doi:10.1016/j.ccr.2013.05.003.PubMedCrossRef

47.

Haferkamp, S., Borst, A., Adam, C., Becker, T. M., Motschenbacher, S., Windhovel, S., et al. (2013). Vemurafenib induces senescence features in melanoma cells. The Journal of Investigative Dermatology, 133(6), 1601–1609. doi:10.1038/jid.2013.6.PubMedCrossRef

48.

Widmer, D. S., Hoek, K. S., Cheng, P. F., Eichhoff, O. M., Biedermann, T., Raaijmakers, M. I., et al. (2013). Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. The Journal of Investigative Dermatology, 133(10), 2436–2443. doi:10.1038/jid.2013.115.PubMedCrossRef

49.

Lito, P., Pratilas, C. A., Joseph, E. W., Tadi, M., Halilovic, E., Zubrowski, M., et al. (2012). Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell, 22(5), 668–682. doi:10.1016/j.ccr.2012.10.009.PubMedPubMedCentralCrossRef

50.

Gopal, Y. N., Deng, W., Woodman, S. E., Komurov, K., Ram, P., Smith, P. D., et al. (2010). Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Research, 70(21), 8736–8747. doi:10.1158/0008-5472.CAN-10-0902.PubMedPubMedCentralCrossRef

51.

Haq, R., Shoag, J., Andreu-Perez, P., Yokoyama, S., Edelman, H., Rowe, G. C., et al. (2013). Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell, 23(3), 302–315. doi:10.1016/j.ccr.2013.02.003.PubMedPubMedCentralCrossRef

52.

Abel, E. V., Basile, K. J., Kugel 3rd, C. H., Witkiewicz, A. K., Le, K., Amaravadi, R. K., et al. (2013). Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. The Journal of Clinical Investigation, 123(5), 2155–2168. doi:10.1172/JCI65780.PubMedPubMedCentralCrossRef

53.

Dummer, R., & Flaherty, K. T. (2012). Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. [research support, non-U.S. Gov’t review]. Current Opinion in Oncology, 24(2), 150–154. doi:10.1097/CCO.0b013e32834fca92.PubMedCrossRef

54.

Frederick, D. T., Salas Fragomeni, R. A., Schalck, A., Ferreiro-Neira, I., Hoff, T., Cooper, Z. A., et al. (2014). Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 Mimetics. PloS One, 9(7), e101286. doi:10.1371/journal.pone.0101286.PubMedPubMedCentralCrossRef

55.

Haq, R., Yokoyama, S., Hawryluk, E. B., Jonsson, G. B., Frederick, D. T., McHenry, K., et al. (2013). BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. [research support, N.I.H., extramural research support, non-U.S. Gov’t]. Proceedings of the National Academy of Sciences of the United States of America, 110(11), 4321–4326. doi:10.1073/pnas.1205575110.PubMedPubMedCentralCrossRef

56.

Muller, J., Krijgsman, O., Tsoi, J., Robert, L., Hugo, W., Song, C., et al. (2014). Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nature Communications, 5, 5712. doi:10.1038/ncomms6712.PubMedPubMedCentralCrossRef

57.

Smith, M. P., Brunton, H., Rowling, E. J., Ferguson, J., Arozarena, I., Miskolczi, Z., et al. (2016). Inhibiting drivers of non-mutational drug tolerance is a salvage strategy for targeted melanoma therapy. Cancer Cell, 29(3), 270–284. doi:10.1016/j.ccell.2016.02.003.PubMedPubMedCentralCrossRef

58.

Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., et al. (2015). Therapy-induced tumour secretomes promote resistance and tumour progression. Nature, 520(7547), 368–372. doi:10.1038/nature14336.PubMedPubMedCentralCrossRef

59.

Martin, S., Dudek-Peric, A. M., Maes, H., Garg, A. D., Gabrysiak, M., Demirsoy, S., et al. (2015). Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells. Biochemical Pharmacology, 93(3), 290–304. doi:10.1016/j.bcp.2014.12.003.PubMedCrossRef

60.

Hirata, E., Girotti, M. R., Viros, A., Hooper, S., Spencer-Dene, B., Matsuda, M., et al. (2015). Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell, 27(4), 574–588. doi:10.1016/j.ccell.2015.03.008.PubMedPubMedCentralCrossRef

61.

Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel 3rd, C. H., et al. (2016). sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature, 532(7598), 250–254. doi:10.1038/nature17392.PubMedPubMedCentralCrossRef

62.

Zhang, T., Dutton-Regester, K., Brown, K. M., & Hayward, N. K. (2016). The genomic landscape of cutaneous melanoma. Pigment Cell & Melanoma Research, 29(3), 266–283. doi:10.1111/pcmr.12459.CrossRef

63.

Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature, 463(7278), 191–196. doi:10.1038/nature08658.PubMedCrossRef

64.

Pfeifer, G. P., You, Y. H., & Besaratinia, A. (2005). Mutations induced by ultraviolet light. Mutation Research, 571(1–2), 19–31. doi:10.1016/j.mrfmmm.2004.06.057.PubMedCrossRef

65.

Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics, 44(9), 1006–1014. doi:10.1038/ng.2359.PubMedPubMedCentralCrossRef

66.

Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J. P., et al. (2012). A landscape of driver mutations in melanoma. Cell, 150(2), 251–263. doi:10.1016/j.cell.2012.06.024.PubMedPubMedCentralCrossRef

67.

Viros, A., Sanchez-Laorden, B., Pedersen, M., Furney, S. J., Rae, J., Hogan, K., et al. (2014). Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53. Nature, 511(7510), 478–482. doi:10.1038/nature13298.PubMedPubMedCentralCrossRef

68.

Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., et al. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature, 485(7399), 502–506. doi:10.1038/nature11071.PubMedPubMedCentral

69.

Huang, F. W., Hodis, E., Xu, M. J., Kryukov, G. V., Chin, L., & Garraway, L. A. (2013). Highly recurrent TERT promoter mutations in human melanoma. Science, 339(6122), 957–959. doi:10.1126/science.1229259.PubMedPubMedCentralCrossRef

70.

Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., et al. (2013). TERT promoter mutations in familial and sporadic melanoma. Science, 339(6122), 959–961. doi:10.1126/science.1230062.PubMedCrossRef

71.

Sanborn, J. Z., Chung, J., Purdom, E., Wang, N. J., Kakavand, H., Wilmott, J. S., et al. (2015). Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America, 112(35), 10995–11000. doi:10.1073/pnas.1508074112.PubMedPubMedCentralCrossRef

72.

Harbst, K., Lauss, M., Cirenajwis, H., Isaksson, K., Rosengren, F., Törngren, T., et al. (2016). Multiregion whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma. Cancer Research, 76(16), 4765–4774. doi:10.1158/0008-5472.CAN-15-3476.PubMedCrossRef

73.

Network, C. G. A. (2015). Genomic classification of cutaneous melanoma. Cell, 161(7), 1681–1696. doi:10.1016/j.cell.2015.05.044.CrossRef

74.

Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., et al. (2015). Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 47(12), 1408–1410. doi:10.1038/ng.3427.PubMedPubMedCentralCrossRef

75.

Krauthammer, M., Kong, Y., Bacchiocchi, A., Evans, P., Pornputtapong, N., Wu, C., et al. (2015). Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nature Genetics, 47(9), 996–1002. doi:10.1038/ng.3361.PubMedPubMedCentralCrossRef

76.

Halaban, R., & Krauthammer, M. (2016). RASopathy gene mutations in melanoma. The Journal of Investigative Dermatology, 136(9), 1755–1759. doi:10.1016/j.jid.2016.05.095.PubMedCrossRef

77.

Shain, A. H., Yeh, I., Kovalyshyn, I., Sriharan, A., Talevich, E., Gagnon, A., et al. (2015). The genetic evolution of melanoma from precursor lesions. The New England Journal of Medicine, 373(20), 1926–1936. doi:10.1056/NEJMoa1502583.PubMedCrossRef

78.

Berger, M. F., Levin, J. Z., Vijayendran, K., Sivachenko, A., Adiconis, X., Maguire, J., et al. (2010). Integrative analysis of the melanoma transcriptome. Genome Research, 20(4), 413–427. doi:10.1101/gr.103697.109.PubMedPubMedCentralCrossRef

79.

Widmer, D. S., Cheng, P. F., Eichhoff, O. M., Belloni, B. C., Zipser, M. C., Schlegel, N. C., et al. (2012). Systematic classification of melanoma cells by phenotype-specific gene expression mapping. Pigment Cell & Melanoma Research, 25(3), 343–353. doi:10.1111/j.1755-148X.2012.00986.x.CrossRef

80.

Hoek, K. S., Eichhoff, O. M., Schlegel, N. C., Dobbeling, U., Kobert, N., Schaerer, L., et al. (2008). In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Research, 68(3), 650–656.PubMedCrossRef

81.

Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., et al. (2015). Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nature Communications, 6, 6683. doi:10.1038/ncomms7683.PubMedPubMedCentralCrossRef

82.

Shakhova, O., Cheng, P., Mishra, P. J., Zingg, D., Schaefer, S. M., Debbache, J., et al. (2015). Antagonistic cross-regulation between Sox9 and Sox10 controls an anti-tumorigenic program in melanoma. PLoS Genetics, 11(1), e1004877. doi:10.1371/journal.pgen.1004877.PubMedPubMedCentralCrossRef

83.

Cheng, P., Shahkova, O., Widmer, D., Eichhoff, O., Zingg, D., Frommel, S., et al. (2015). Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology, 16(1), 42.PubMedPubMedCentralCrossRef

84.

Cheng, P. F., Shakhova, O., Widmer, D. S., Eichhoff, O. M., Zingg, D., Frommel, S. C., et al. (2015). Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma. Genome Biology, 16, 42. doi:10.1186/s13059-015-0594-4.PubMedPubMedCentralCrossRef

85.

Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., et al. (2016). Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science, 352(6282), 189–196. doi:10.1126/science.aad0501.PubMedPubMedCentralCrossRef

86.

Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology, 29(22), 3085–3096. doi:10.1200/JCO.2010.33.2312.PubMedPubMedCentralCrossRef

87.

Shi, H., Moriceau, G., Kong, X., Lee, M. K., Lee, H., Koya, R. C., et al. (2012). Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications, 3, 724. doi:10.1038/ncomms1727.PubMedPubMedCentralCrossRef

88.

Chiappetta, C., Proietti, I., Soccodato, V., Puggioni, C., Zaralli, R., Pacini, L., et al. (2015). BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma. Applied Immunohistochemistry & Molecular Morphology, 23(3), 172–177. doi:10.1097/PAI.0000000000000071.

89.

Hugo, W., Shi, H., Sun, L., Piva, M., Song, C., Kong, X., et al. (2015). Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell, 162(6), 1271–1285. doi:10.1016/j.cell.2015.07.061.PubMedPubMedCentralCrossRef

90.

Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014). Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy. Cancer Research, 74(21), 5937–5941. doi:10.1158/0008-5472.CAN-14-1174.PubMedCrossRef

91.

Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth 2nd, M. H., Treacy, D., Trombetta, J. J., et al. (2016). Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science, 352(6282), 189–196. doi:10.1126/science.aad0501.PubMedPubMedCentralCrossRef

92.

Dummer, R., Hauschild, A., Lindenblatt, N., Pentheroudakis, G., & Keilholz, U. (2015). Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 26(Suppl 5), v126–v132. doi:10.1093/annonc/mdv297.PubMedCrossRef

93.

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., et al. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science, 350(6257), 207–211. doi:10.1126/science.aad0095.PubMedPubMedCentralCrossRef

94.

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., et al. (2016). Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell, 165(1), 35–44. doi:10.1016/j.cell.2016.02.065.PubMedPubMedCentralCrossRef

95.

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., et al. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348(6230), 124–128. doi:10.1126/science.aaa1348.PubMedPubMedCentralCrossRef

96.

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., et al. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine, 372(26), 2509–2520. doi:10.1056/NEJMoa1500596.PubMedPubMedCentralCrossRef

97.

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., et al. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. New England Journal of Medicine, 375(9), 819–829. doi:10.1056/NEJMoa1604958.PubMedPubMedCentralCrossRef

98.

Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology, 3(11), 991–998.PubMedCrossRef

99.

Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., et al. (2016). Mutations associated with acquired resistance to PD-1 blockade in melanoma. The New England Journal of Medicine. doi:10.1056/NEJMoa1604958.PubMedPubMedCentral

100.

Raaijmakers, M. I., Widmer, D. S., Maudrich, M., Koch, T., Langer, A., Flace, A., et al. (2015). A new live-cell biobank workflow efficiently recovers heterogeneous melanoma cells from native biopsies. Experimental Dermatology, 24(5), 377–380. doi:10.1111/exd.12683.PubMedCrossRef

101.

Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007). Melanoma biology and new targeted therapy. Nature, 445(7130), 851–857.PubMedCrossRef

102.

Hill, D. S., Robinson, N. D., Caley, M. P., Chen, M., O'Toole, E. A., Armstrong, J. L., et al. (2015). A novel fully humanized 3D skin equivalent to model early melanoma invasion. Molecular Cancer Therapeutics, 14(11), 2665–2673. doi:10.1158/1535-7163.MCT-15-0394.PubMedPubMedCentralCrossRef

103.

Ramgolam, K., Lauriol, J., Lalou, C., Lauden, L., Michel, L., de la Grange, P., et al. (2011). Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function. PloS One, 6(4), e18784. doi:10.1371/journal.pone.0018784.PubMedPubMedCentralCrossRef

104.

Johnson, J. I., Decker, S., Zaharevitz, D., Rubinstein, L. V., Venditti, J. M., Schepartz, S., et al. (2001). Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British Journal of Cancer, 84(10), 1424–1431. doi:10.1054/bjoc.2001.1796.PubMedPubMedCentralCrossRef

105.

Beaumont, K. A., Mohana-Kumaran, N., & Haass, N. K. (2013). Modeling melanoma in vitro and in vivo. Healthcare (Basel), 2(1), 27–46. doi:10.3390/healthcare2010027.CrossRef

106.

Nyga, A., Cheema, U., & Loizidou, M. (2011). 3D tumour models: novel in vitro approaches to cancer studies. J Cell Commun Signal, 5(3), 239–248. doi:10.1007/s12079-011-0132-4.PubMedPubMedCentralCrossRef

107.

Ghosh, S., Spagnoli, G. C., Martin, I., Ploegert, S., Demougin, P., Heberer, M., et al. (2005). Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. Journal of Cellular Physiology, 204(2), 522–531. doi:10.1002/jcp.20320.PubMedCrossRef

108.

Cody, N. A., Zietarska, M., Filali-Mouhim, A., Provencher, D. M., Mes-Masson, A. M., & Tonin, P. N. (2008). Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines. BMC Medical Genomics, 1, 34. doi:10.1186/1755-8794-1-34.PubMedPubMedCentralCrossRef

109.

Thurber, A. E., Douglas, G., Sturm, E. C., Zabierowski, S. E., Smit, D. J., Ramakrishnan, S. N., et al. (2011). Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene, 30(27), 3036–3048. doi:10.1038/onc.2011.33.PubMedPubMedCentralCrossRef

110.

Zhuang, L., Lee, C. S., Scolyer, R. A., McCarthy, S. W., Palmer, A. A., Zhang, X. D., et al. (2005). Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. Journal of Clinical Pathology, 58(11), 1163–1169. doi:10.1136/jcp.2005.025957.PubMedPubMedCentralCrossRef

111.

Weiswald, L. B., Bellet, D., & Dangles-Marie, V. (2015). Spherical cancer models in tumor biology. Neoplasia, 17(1), 1–15. doi:10.1016/j.neo.2014.12.004.PubMedPubMedCentralCrossRef

112.

Thoma, C. R., Zimmermann, M., Agarkova, I., Kelm, J. M., & Krek, W. (2014). 3D cell culture systems modeling tumor growth determinants in cancer target discovery. Advanced Drug Delivery Reviews, 69-70, 29–41. doi:10.1016/j.addr.2014.03.001.PubMedCrossRef

113.

Saltari, A., Truzzi, F., Quadri, M., Lotti, R., Palazzo, E., Grisendi, G., et al. (2016). CD271 down-regulation promotes melanoma progression and invasion in three-dimensional models and in zebrafish. The Journal of Investigative Dermatology. doi:10.1016/j.jid.2016.05.116.PubMed

114.

Smalley, K. S., Lioni, M., Noma, K., Haass, N. K., & Herlyn, M. (2008). In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opin Drug Discov, 3(1), 1–10. doi:10.1517/17460441.3.1.1.PubMedCrossRef

115.

Vinci, M., Gowan, S., Boxall, F., Patterson, L., Zimmermann, M., Court, W., et al. (2012). Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC Biology, 10, 29. doi:10.1186/1741-7007-10-29.PubMedPubMedCentralCrossRef

116.

Quintana, E., Shackleton, M., Sabel, M. S., Fullen, D. R., Johnson, T. M., & Morrison, S. J. (2008). Efficient tumour formation by single human melanoma cells. Nature, 456(7222), 593–598. doi:10.1038/nature07567.PubMedPubMedCentralCrossRef

117.

Yu, M., Bardia, A., Aceto, N., Bersani, F., Madden, M. W., Donaldson, M. C., et al. (2014). Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science, 345(6193), 216–220. doi:10.1126/science.1253533.PubMedPubMedCentralCrossRef

118.

Kim, K. U., Wilson, S. M., Abayasiriwardana, K. S., Collins, R., Fjellbirkeland, L., Xu, Z., et al. (2005). A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. American Journal of Respiratory Cell and Molecular Biology, 33(6), 541–548. doi:10.1165/rcmb.2004-0355OC.PubMedPubMedCentralCrossRef

119.

De Wever, O., Hendrix, A., De Boeck, A., Westbroek, W., Braems, G., Emami, S., et al. (2010). Modeling and quantification of cancer cell invasion through collagen type I matrices. The International Journal of Developmental Biology, 54(5), 887–896. doi:10.1387/ijdb.092948ow.PubMedCrossRef

120.

Mehta, G., Hsiao, A. Y., Ingram, M., Luker, G. D., & Takayama, S. (2012). Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. Journal of Controlled Release, 164(2), 192–204. doi:10.1016/j.jconrel.2012.04.045.PubMedPubMedCentralCrossRef

121.

Berking, C., & Herlyn, M. (2001). Human skin reconstruct models: a new application for studies of melanocyte and melanoma biology. Histology and Histopathology, 16(2), 669–674.PubMed

122.

Lee, J. T., Li, L., Brafford, P. A., van den Eijnden, M., Halloran, M. B., Sproesser, K., et al. (2010). PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. Pigment Cell & Melanoma Research, 23(6), 820–827. doi:10.1111/j.1755-148X.2010.00763.x.CrossRef

123.

Enriquez-Navas, P. M., Kam, Y., Das, T., Hassan, S., Silva, A., Foroutan, P., et al. (2016). Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer. Science Translational Medicine, 8(327), 327ra324. doi:10.1126/scitranslmed.aad7842.CrossRef

124.

Das Thakur, M., Salangsang, F., Landman, A. S., Sellers, W. R., Pryer, N. K., Levesque, M. P., et al. (2013). Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature, 494(7436), 251–255. doi:10.1038/nature11814.PubMedCrossRef

125.

Li, F. Z., Dhillon, A. S., Anderson, R. L., McArthur, G., & Ferrao, P. T. (2015). Phenotype switching in melanoma: implications for progression and therapy. Frontiers in Oncology, 5(31). doi:10.3389/fonc.2015.00031

126.

Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews. Clinical Oncology, 10(8), 472–484. doi:10.1038/nrclinonc.2013.110.PubMedCrossRef

Titel: Metastatic melanoma moves on: translational science in the era of personalized medicine
verfasst von: Mitchell P. Levesque
Phil F. Cheng
Marieke I.G. Raaijmakers
Annalisa Saltari
Reinhard Dummer
Publikationsdatum: 20.03.2017
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2017
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-017-9658-0

Neu im Fachgebiet Onkologie

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Metastatic melanoma moves on: translational science in the era of personalized medicine

Abstract

Neu im Fachgebiet Onkologie

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Update Onkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Anesthetic technique and cancer recurrence in oncologic surgery: unraveling the puzzle

Crosstalk signaling in targeted melanoma therapy

Identification, genetic testing, and management of hereditary melanoma

Biographies

Next generation predictive biomarkers for immune checkpoint inhibition

Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma

Neu im Fachgebiet Onkologie

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

Update Onkologie